OSIVAX
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • LEGAL MENTIONS

ABOUT US

eXECUTIVE COMMITTEE
SCIENTIFIC ADVISORY BOARD
PARTNERS
​
​
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T-cell responses
​
Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, in order to accelerate the development of the R&D pipeline
Picture
oligoDOM® technology platform leverages: 
  • More than 10 years of R&D on a breakthrough approach to induce CD8 T-cell immunity
  • A promising lead candidate of universal influenza vaccine
  • Additional development opportunities, especially in cancer immunotherapies​

Osivax lead program is a game-changing universal influenza vaccine
  • Leveraging oligoDOM® technology, Osivax’s team is developing a standalone recombinant vaccine to prevent moderate to severe cases of seasonal and pandemic influenza
  • This oligoDOM®-based universal influenza vaccine induces powerful CD8 T-cell immune responses against the highly conserved flu NucleoProtein (NP) and won’t require annual updates as NP is a highly conserved antigen
  • The aim of this universal Influenza vaccine is to provide greater than 70% protection from morbidity and mortality caused by current and future A- and B-strain influenza viruses (1)

Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertises
​
Osivax remains open to collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens


(1) Hayward AC, Wang L, Goonetilleke N, et al. Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015;191(12):1422-1431. doi:10.1164/rccm.201411-1988OC.

Legal mentions
Contact us
Proudly powered by Weebly
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • LEGAL MENTIONS